Research Article
Antifungal Susceptibility and Biofilm Production of Candida spp. Isolated from Clinical Samples
Table 4
Antifungal susceptibility testing of Candida species.
| | Antifungal agents | Candida species | Total (N = 90) | | C. albicans (N = 41) | C. tropicalis (N = 26) | C. krusei (N = 18) | C. glabrata (N = 3) | C. parapsilosis (N = 2) |
| | Amphotericin B | S | 41 (100%) | 26 (100%) | 18 (100%) | 3 (100%) | 2 (100%) | 90 (100%) | | R | — | — | — | — | — | — | | Fluconazole | S | 32 (47.05%) | 18 (26.47%) | 13 (19.11%) | 3 (100%) | 2 (100%) | 68 (75.55%) | | R | 9 (40.90%) | 8 (36.36%) | 5 (22.72%) | — | — | 22 (24.44%) | | Voriconazole | S | 34 (46.57%) | 19 (26.02%) | 15 (20.54%) | 3 (100%) | 2 (100%) | 73 (81.11%) | | R | 7 (41.17%) | 7 (41.17%) | 3 (17.64%) | — | — | 17 (18.88%) |
|
|
S = susceptible; R = resistant.
|
